CBD and Legal Facts — What You Need to Know | SEABEDEE

CBD and Legal Facts — What You Need to Know | SEABEDEE

The 2018 Farm Bill federally legalised hemp-derived CBD containing ≤0.3% THC. Yet CBD's legal status remains one of the most misunderstood topics in consumer wellness. Federal legalisation does not mean unrestricted access. State laws, product formulation, and THC content create a three-layer legal framework that determines whether CBD is permissible in your jurisdiction. A product legal in Colorado may be prohibited in Idaho. A tincture with 0.29% THC is federally compliant; one with 0.35% THC is a controlled substance.

We've guided thousands of customers through CBD's legal landscape since 2016. The confusion isn't accidental. Overlapping federal and state regulations, inconsistent enforcement, and evolving case law mean the legal status of CBD products shifts depending on where you live, how the product is formulated, and what claims the seller makes.

What is the legal status of CBD in the United States?

CBD derived from hemp (Cannabis sativa L. with ≤0.3% THC) is federally legal under the 2018 Farm Bill, but individual states retain authority to restrict or prohibit CBD sales within their borders. As of 2026, three states. Idaho, Nebraska, and South Dakota. Maintain restrictions on CBD products despite federal legalisation. The legal threshold is precise: 0.3% delta-9 THC by dry weight. Exceeding that limit, even by 0.01%, reclassifies the product as a Schedule I controlled substance under the Controlled Substances Act.

CBD's federal legalisation is not a blanket permission slip. It's a conditional framework that hinges on three specific requirements: hemp source, THC content, and state-level compliance. The 2018 Farm Bill removed hemp from the Controlled Substances Act. But only if it meets the 0.3% THC threshold. The DEA still classifies cannabis-derived CBD (from marijuana plants) as Schedule I. The FDA regulates CBD as a drug ingredient, not a supplement, which is why CBD cannot legally be added to food or marketed with medical claims without prior approval.

The 2018 Farm Bill and What It Actually Changed

The Agriculture Improvement Act of 2018. Commonly called the Farm Bill. Removed hemp and hemp-derived compounds from Schedule I classification, provided they contain no more than 0.3% delta-9 THC on a dry weight basis. This threshold is not arbitrary. It was adopted from a 1976 Canadian research paper that established 0.3% THC as the dividing line between industrial hemp and psychoactive cannabis. The Farm Bill legalised hemp cultivation under state-approved programmes, established a federal licensing framework through USDA oversight, and permitted interstate transport of hemp-derived products. But it did not override state authority to regulate or prohibit CBD within state borders.

Our team has reviewed compliance documentation for hundreds of CBD products. The brands that operate legally are not the ones making the boldest claims. They're the ones that can produce Certificates of Analysis (COAs) from ISO 17025-accredited laboratories showing THC content below 0.3%, batch-by-batch. SEABEDEE publishes third-party lab results for every product batch at Lab Results because federal compliance requires verifiable THC testing, not just a marketing claim.

The Farm Bill did not legalise all cannabinoids. Delta-8 THC, Delta-10 THC, and THC-O remain in legal grey areas because they are often synthesised from CBD isolate rather than naturally extracted from hemp. The DEA issued an Interim Final Rule in 2020 clarifying that 'synthetically derived' cannabinoids remain Schedule I substances, even if the starting material is federally legal hemp. The distinction matters: naturally occurring cannabinoids in hemp extract are legal if total THC is ≤0.3%; chemically converted cannabinoids may not be, regardless of the source.

State-Level CBD Laws and Where Restrictions Still Apply

Federal legalisation does not preempt state law. As of 2026, Idaho Code § 37-2701 defines all cannabis as a Schedule I substance with no exception for hemp-derived CBD. Nebraska Revised Statute § 28-401 permits industrial hemp cultivation but restricts CBD product sales to prescription-only channels. South Dakota initially prohibited CBD entirely; a 2020 ballot measure legalised medical cannabis, but recreational CBD sales remain restricted under SDCL § 22-42-1. These three states enforce active bans or severe restrictions despite federal legalisation.

An additional 14 states impose regulatory frameworks that limit CBD product types, allowable formulations, or sales channels. Texas permits CBD but restricts Delta-8 THC under Texas Health and Safety Code § 443.001. Georgia allows CBD oil sales under the Haleigh's Hope Act but restricts THC content to 0.3% or lower and limits sales to registered dispensaries for certain medical conditions. Virginia legalised adult-use cannabis in 2021, which expanded CBD access. But edibles and beverages containing CBD remain subject to Virginia ABC regulations that differ from federal guidance.

The highest-risk scenario for consumers is purchasing CBD in a state where it is legal but travelling to a state where it is not. Federal law permits interstate transport of hemp-derived CBD, but state law governs possession within state borders. Crossing from Colorado (where recreational cannabis is legal) into Wyoming (where only CBD with 0.0% THC is permitted) with a full-spectrum tincture creates a state-level possession violation, even if the product is federally compliant. We've advised customers to verify the legal status in both their home state and any state they plan to visit before travelling with CBD.

Full-Spectrum, Broad-Spectrum, and Isolate — Legal Differences Explained

Full-spectrum CBD contains all naturally occurring cannabinoids, terpenes, and up to 0.3% THC. Broad-spectrum CBD contains multiple cannabinoids and terpenes but with THC removed to non-detectable levels (typically <0.01%). CBD isolate is 99%+ pure cannabidiol with all other compounds stripped out. The legal difference is THC content. Full-spectrum products are federally legal only if total THC is ≤0.3%, while broad-spectrum and isolate formulations contain no detectable THC and face fewer state-level restrictions.

Employers, athletic organisations, and federal agencies often prohibit THC entirely, even at trace levels. The World Anti-Doping Agency (WADA) removed CBD from its Prohibited List in 2018 but continues to ban THC. A full-spectrum product with 0.25% THC is federally legal but may trigger a positive drug test depending on dosage, metabolism, and test sensitivity. Broad-spectrum formulations like SEABEDEE's Sour Neon CBD Gummies and isolate-based products eliminate THC-related legal risk for individuals subject to drug testing.

Lab testing standards determine whether a product meets the 0.3% threshold. ISO 17025 accreditation is the gold standard. It requires validated testing methods, proficiency testing, and third-party oversight. Non-accredited labs may produce inaccurate COAs, which exposes both the manufacturer and the consumer to legal risk. A product labelled 0.29% THC that actually contains 0.35% THC is a controlled substance. And the seller, not the buyer, typically faces enforcement action. SEABEDEE uses ISO 17025-accredited laboratories for all batch testing because accuracy is not optional when the legal threshold is measured in hundredths of a percent.

CBD and Legal Facts: Employer Policies, Drug Testing, and Federal Agencies

Federal employees are prohibited from using CBD under Department of Defense (DoD) and Department of Transportation (DOT) policies, despite federal legalisation. DoD Instruction 1010.01 bans all cannabis-derived products, including hemp-derived CBD, for active-duty military personnel. The DOT's Drug and Alcohol Testing Regulation (49 CFR Part 40) prohibits safety-sensitive employees from using any product that could result in a positive THC test. The Transportation Security Administration (TSA) updated its policy in 2019 to permit CBD in carry-on and checked baggage if it is hemp-derived and contains ≤0.3% THC. But TSA officers may still refer products to law enforcement if packaging is unclear or if state law at the destination airport prohibits CBD.

Private employers are not bound by federal legalisation when setting workplace policies. Most large corporations prohibit THC use entirely, and some extend that prohibition to CBD products containing trace THC. A 2023 survey conducted by the Society for Human Resource Management (SHRM) found that 62% of employers with drug-free workplace policies do not make exceptions for CBD, even when derived from legal hemp. Employees who use full-spectrum CBD products face termination risk if they test positive for THC, regardless of federal or state CBD legalisation.

Drug test sensitivity varies by method. Standard immunoassay urine tests flag THC metabolites at 50 ng/mL. The federal workplace cutoff. Gas chromatography-mass spectrometry (GC-MS) confirmation tests detect THC-COOH, the primary metabolite, at 15 ng/mL. A daily dose of 60 mg of full-spectrum CBD containing 0.3% THC (roughly 0.18 mg THC per dose) can produce detectable THC metabolites in chronic users after 7–10 days of continuous use, according to research published in JAMA Network Open in 2020. Broad-spectrum and isolate formulations eliminate this risk. Which is why SEABEDEE offers THC-free options like CBD Isolate Capsules for customers subject to workplace testing.

Marketing Claims, FDA Regulation, and What Sellers Cannot Legally Say

The FDA regulates CBD as a drug ingredient, not a dietary supplement, which means CBD cannot be legally marketed with disease treatment or prevention claims without prior FDA approval. Epidiolex. A CBD-based medication approved in 2018 for treating seizures associated with Lennox-Gastaut syndrome and Dravet syndrome. Is the only FDA-approved CBD drug as of 2026. All other CBD products cannot legally claim to 'treat,' 'cure,' 'prevent,' or 'diagnose' any disease or medical condition under the Federal Food, Drug, and Cosmetic Act (FD&C Act).

The FDA sent over 200 warning letters to CBD companies between 2019 and 2024 for making unapproved health claims. Common violations include marketing CBD for anxiety, depression, pain relief, inflammation, cancer, Alzheimer's disease, or opioid withdrawal without supporting clinical evidence or FDA authorisation. A product marketed as 'CBD oil for arthritis pain' is considered an unapproved new drug subject to FDA enforcement action, regardless of whether the CBD itself is hemp-derived and federally legal.

Our team structures all product descriptions to comply with FDA guidance. We describe CBD's general properties and explain how customers use it without making medical claims. For example, SEABEDEE's CBD Calming Blend is marketed as a formulation that combines CBD with botanicals traditionally used for relaxation. But we do not claim it treats anxiety disorder, which would trigger FDA scrutiny. Educating customers on compliance protects both the business and the buyer from legal risk.

The Federal Trade Commission (FTC) enforces truth-in-advertising standards for CBD products. Companies making unsubstantiated efficacy claims face FTC action even if they avoid explicit disease claims. In 2022, the FTC issued a policy statement on health-related endorsements requiring 'competent and reliable scientific evidence' for any claim that a product affects health, structure, or function. Testimonials from customers claiming CBD 'cured' their condition expose sellers to FTC liability unless the claim is supported by randomised controlled trials (RCTs) meeting FDA standards.

CBD and Legal Facts: Product Comparison

Key Takeaways

• The 2018 Farm Bill legalised hemp-derived CBD federally, but only if total delta-9 THC content is ≤0.3% by dry weight. Exceeding that threshold by any amount reclassifies the product as a Schedule I controlled substance.
• Three states (Idaho, Nebraska, South Dakota) maintain active restrictions on CBD despite federal legalisation, and 14 additional states impose regulatory frameworks limiting product types or sales channels.
• Full-spectrum CBD products contain trace THC and can trigger positive drug tests in chronic users, while broad-spectrum and isolate formulations eliminate THC-related legal and employment risk.
• The FDA regulates CBD as a drug ingredient, prohibiting all disease treatment or prevention claims unless the product has received prior FDA approval like Epidiolex.
• ISO 17025-accredited lab testing is the only reliable method to verify THC content and federal compliance. Non-accredited COAs expose both manufacturers and consumers to legal risk.
• Federal employees under DoD and DOT regulations are prohibited from using CBD entirely, and 62% of private employers with drug-free workplace policies do not make exceptions for hemp-derived CBD.

What If: CBD and Legal Facts Scenarios

What If I Travel Across State Lines with CBD?

Verify the legal status in both your departure and destination states before travelling. Federal law permits interstate transport of hemp-derived CBD, but possession within a state where CBD is restricted violates state law. If your destination state prohibits CBD (Idaho, Nebraska, South Dakota), leave the product at home. If the destination permits CBD but restricts THC content below federal limits (e.g., Texas restricts Delta-8 THC), ensure your product is broad-spectrum or isolate-based with a current COA showing non-detectable THC. TSA permits CBD in carry-on and checked baggage if packaging clearly indicates hemp origin and ≤0.3% THC, but state law governs what happens after you land.

What If My Employer Prohibits CBD Use?

Employer policies override federal legalisation. If your workplace prohibits cannabis-derived products or conducts THC testing, full-spectrum CBD products create termination risk regardless of federal legality. Switch to broad-spectrum or isolate formulations with non-detectable THC, and request written confirmation from your HR department on whether THC-free CBD is permitted. If your employer prohibits all cannabinoids, compliance with company policy is legally required to maintain employment. Federal CBD legalisation does not protect employees from workplace policy enforcement.

What If I'm Drug Tested After Using Full-Spectrum CBD?

Full-spectrum CBD products containing 0.3% THC can produce positive drug tests in chronic users, typically after 7–10 days of continuous high-dose use. If you test positive, request GC-MS confirmation testing (more accurate than immunoassay screening) and provide your employer or testing authority with a COA showing the product's THC content. Some employers accept CBD explanations; most do not. The safest approach: switch to broad-spectrum or isolate products if you are subject to any form of drug testing. SEABEDEE's CBD Isolate Capsules contain zero THC and eliminate this risk entirely.

The Blunt Truth About CBD and Legal Status

Here's the honest answer: federal legalisation of hemp-derived CBD does not mean unrestricted access, and it does not protect you from employer policies, state-level restrictions, or drug test consequences. The 2018 Farm Bill legalised CBD under specific conditions. But those conditions include a precise THC threshold, third-party lab verification, and compliance with state law in your jurisdiction. A product that is legal to manufacture in Oregon may be illegal to possess in Idaho. A tincture that is federally compliant may still result in termination if your employer prohibits THC exposure.

The brands that operate responsibly are not the ones making the boldest claims. They're the ones publishing COAs from accredited labs, formulating products to eliminate THC-related risk, and educating customers on the legal framework rather than oversimplifying it. Federal legalisation is a starting point, not a finish line. Verify your state's laws. Verify your employer's policies. Verify the lab results before purchasing. Those three steps prevent 95% of the legal complications customers encounter with CBD.

CBD's legal landscape is not static. State legislatures revise hemp laws annually. The FDA issues updated guidance on enforcement priorities. Employers adjust drug-free workplace policies in response to evolving case law. Staying legally compliant requires ongoing verification. Not a one-time assumption that 'CBD is legal now.' It is legal under specific conditions. Know those conditions before purchasing, before travelling, and before using CBD in any context where legal or employment consequences could follow.

If you're navigating CBD's legal landscape and want products formulated for compliance, explore SEABEDEE's complete collection of third-party tested, hemp-derived CBD at Continue Shopping. Every product batch includes lab-verified THC content, transparent sourcing, and formulations designed to meet federal and state-level requirements. Browse our full inventory of natural solutions designed to help you feel your best, inside and out.